The leuprolide flare regime for in-vitro fertilization/gamete intra-fallopian transfer and embryo cryopreservation.
Gonadotrophin releasing hormone agonists (GnRHa) are now well established as adjuvant agents for in-vitro fertilization (IVF)/gamete intra-Fallopian transfer (GIFT) but several different modes of usage have been proposed. Our experience with 328 cycles of leuprolide used in a flare regime is reviewed. An endocrinologically proven flare effect was associated with a reduction of human menopausal gonadotrophin (HMG) usage (10 versus 16 ampoules) and a lower cycle cancellation/conversion rate (7.4 versus 11.3%). Overall, satisfactory rates of oocyte recovery (93%, mean number of oocytes 7.0), clinical pregnancy (24.4% per oocyte recovery) and pregnancy from frozen/thawed embryo transfers (14%) were achieved. The flare protocol appears to be a satisfactory choice for the majority of subjects but careful monitoring is required to avoid the potential for ovarian hyperstimulation.
Matthews
C D
CD
Department of Obstetrics and Gynaecology, University of Adelaide, Queen Elizabeth Hospital, South Australia.
Warnes
G M
GM
Norman
R J
RJ
Phillipson
G
G
Kirby
C A
CA
Wang
X
X
D015925:Cryopreservation; D004334:Drug Administration Schedule; D004622:Embryo, Mammalian; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D015181:Gamete Intrafallopian Transfer / Q000379:methods*; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D011863:Radioimmunoassay
D016729:Leuprolide